DK0653942T3 - Morphogen-induceret nerve-regenerering og -reparation - Google Patents

Morphogen-induceret nerve-regenerering og -reparation

Info

Publication number
DK0653942T3
DK0653942T3 DK93918560T DK93918560T DK0653942T3 DK 0653942 T3 DK0653942 T3 DK 0653942T3 DK 93918560 T DK93918560 T DK 93918560T DK 93918560 T DK93918560 T DK 93918560T DK 0653942 T3 DK0653942 T3 DK 0653942T3
Authority
DK
Denmark
Prior art keywords
neurons
mammal
morphogen
stimulating
repair
Prior art date
Application number
DK93918560T
Other languages
Danish (da)
English (en)
Inventor
Charles M Cohen
Hermann Oppermann
Engin Ozkaynak
Thangavel Kuberasampath
David C Rueger
Roy H L Pang
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0653942(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0653942T3 publication Critical patent/DK0653942T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
DK93918560T 1992-07-31 1993-07-29 Morphogen-induceret nerve-regenerering og -reparation DK0653942T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92281392A 1992-07-31 1992-07-31
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/007231 WO1994003200A1 (en) 1992-07-31 1993-07-29 Morphogen-induced nerve regeneration and repair

Publications (1)

Publication Number Publication Date
DK0653942T3 true DK0653942T3 (da) 2003-10-20

Family

ID=27363454

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918560T DK0653942T3 (da) 1992-07-31 1993-07-29 Morphogen-induceret nerve-regenerering og -reparation

Country Status (10)

Country Link
EP (1) EP0653942B2 (ja)
JP (3) JP4344012B2 (ja)
AT (1) ATE242639T1 (ja)
AU (1) AU681594B2 (ja)
CA (1) CA2141554C (ja)
DE (1) DE69333040T3 (ja)
DK (1) DK0653942T3 (ja)
ES (1) ES2201059T5 (ja)
PT (1) PT653942E (ja)
WO (1) WO1994003200A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723698B2 (en) 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
ES2201059T5 (es) * 1992-07-31 2007-11-01 Curis, Inc. Regeneracion y reparacion de nervios inducida por morfogenos.
AU5129293A (en) * 1992-09-15 1994-04-12 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
EP1770161A3 (en) 1993-05-12 2008-04-23 Genetics Institute, LLC BMP-11 compositions
KR100328752B1 (ko) * 1993-08-26 2002-09-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 인간골형태발생단백질을사용한신경재생법
US5669407A (en) * 1994-03-24 1997-09-23 Masco Corporation Of Indiana Compression cartridge for a faucet valve assembly
WO1996030038A1 (en) * 1995-03-29 1996-10-03 The Rockefeller University Peptide growth factor having epidermal inducing activity
EP0894004B2 (en) * 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
AU4726597A (en) * 1996-10-31 1998-05-22 Nippon Shinyaku Co. Ltd. Cranial nerve cell protectives
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
PT980252E (pt) * 1997-05-05 2005-01-31 Curis Inc Terapias para insuficiencia renal aguda
WO1998054572A1 (en) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2000029012A2 (en) † 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
DK1572950T3 (da) 2002-06-17 2013-02-04 Thrasos Inc Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
WO2006009836A2 (en) 2004-06-17 2006-01-26 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
ATE527349T1 (de) * 2004-06-23 2011-10-15 Tissuegene Inc Nervenregeneration
JP2009508532A (ja) 2005-09-20 2009-03-05 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
CA2718592A1 (en) 2008-02-13 2009-08-20 Keith Hruska Method of treating vascular sclerosis
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
MA47163A (fr) * 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243254T1 (de) * 1988-04-08 2003-07-15 Stryker Corp Biosynthetische knochenbildende proteine, und sie enthaltende knochenbildende vorrichtungen
CA2030518C (en) * 1989-03-28 2000-03-21 Elizabeth A. Wang Osteoinductive compositions
EP0652951B1 (en) * 1990-06-15 1999-09-01 Carnegie Institution Of Washington GDF-1and UOG-1 proteins
AU660019B2 (en) * 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
ES2201059T5 (es) * 1992-07-31 2007-11-01 Curis, Inc. Regeneracion y reparacion de nervios inducida por morfogenos.

Also Published As

Publication number Publication date
AU4797193A (en) 1994-03-03
WO1994003200A1 (en) 1994-02-17
ES2201059T5 (es) 2007-11-01
JP2005287512A (ja) 2005-10-20
JPH07509721A (ja) 1995-10-26
CA2141554A1 (en) 1994-02-17
CA2141554C (en) 2003-02-11
EP0653942B2 (en) 2007-03-07
JP4344012B2 (ja) 2009-10-14
EP0653942A1 (en) 1995-05-24
AU681594B2 (en) 1997-09-04
DE69333040T3 (de) 2007-10-11
JP2009227679A (ja) 2009-10-08
ES2201059T3 (es) 2004-03-16
EP0653942B1 (en) 2003-06-11
DE69333040D1 (de) 2003-07-17
DE69333040T2 (de) 2004-05-06
PT653942E (pt) 2003-11-28
ATE242639T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
DK0653942T3 (da) Morphogen-induceret nerve-regenerering og -reparation
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
DK1039802T3 (da) Transdermal terapeutisk anordning med capsicin og capsaicinanaloger
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE58906649D1 (de) Implantierbares medizinisches Gerät mit Mitteln zum Stimulieren von Gewebekontraktionen mit einstellbarer Stimulationsintensität und Verfahren zum Betrieb eines solchen Gerätes.
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
ATE434975T1 (de) Vorrichtung und verfahren zur repositionierung von patienten
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
ATE415977T1 (de) Methode zum screening von anti-amyloidogenen eigenschaften und methode zur behandlung neurodegenerativer krankheiten
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
DE69837622D1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
NO20010390L (no) Behandling av angstsykdommer
RU2196622C2 (ru) Способ и устройство свето-лечения отеков конечностей
BR9708037A (pt) Método para o tratamento de abuso de substância
CY1108922T1 (el) Θεραπεια μελανωματος
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
RU99125726A (ru) Способ лечения токсикомании